MedWatch

Bioporto CEO anticipates two approvals in 2019: “A major disappointment if it doesn’t happen.”

After a number of delays, Danish diagnostics company Bioporto expects to obtain approval of its NGAL test in both children and adults before the end of the year. According to the CEO, it will be a “major disappointment” if the company is to postpone the launch again.

Foto: BioPorto PR

CEO in Bioporto, Peter Mørch Eriksen, is keeping the opportunities open with US authority FDA, which is still evaluating the company’s kidney injury biomarker, the NGAL test.

Bioporto has changed its plans and now anticipates green light for the biomarker for children before it is approved for adults, says the CEO to MedWatch.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier